"Orange Book" Supplement Highlights Levothyroxine Equivalence Codes
This article was originally published in The Pink Sheet Daily
Supplement also adds a Genpharm levothyroxine sodium ANDA to the "Orange Book" chart.
You may also be interested in...
Scheduling the event suggests FDA is re-evaluating its position on the interchangeability of the drug class. Announcement of the May 23 meeting comes nearly one year after the agency approved a number of equivalence claims for levothyroxine sodium products.
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.
Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.